Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.
暂无分享,去创建一个
M. van Glabbeke | A. Hagemeijer | R. Sciot | J. Verweij | M. Glabbeke | M. Debiec‐Rychter | A. V. van Oosterom | M. Stul | I. Judson | S. Dimitrijević | M. Scurr | H. Dumez | B. Wasąg | A. Oosterom | M. Brown | H. Vranck | M. Debiec-Rychter